Automera

Automera is a biotechnology company based in Singapore, founded in 2022.

The company specializes in developing novel therapeutics using autophagy-driven degradation technology, particularly through its AUTAC platform. This platform creates chimeric small molecules that engage autophagy pathways and target specific diseases, allowing for selective degradation of various cellular components. Founded by scientists Loong Wang and Taiyang Zhang, Automera utilizes advanced techniques such as computational chemistry, artificial intelligence, and quantum molecular dynamics in its research and development efforts. The company is currently in the Series A funding stage, having raised $16 million to support its initiatives. Automera's initial focus is on oncology, with plans to explore applications in cancer, inflammation, and central nervous system disorders.